SCOPUS 정보 검색 플랫폼

Heart Failure Reviews

Volumn 13, Issue 4, 2008, Pages 377-378

Introduction: Anemia in heart failure

(1) Anand, Inder a,b

a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL (United States)

b VA MEDICAL CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DRUG SAFETY; EDITORIAL; FLUID RETENTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE REMODELING; HEMATOPOIESIS; HIGH OUTPUT HEART FAILURE; HUMAN; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON THERAPY; MOLECULAR DYNAMICS; OUTCOMES RESEARCH; PREVALENCE; SYSTEMIC VASCULAR RESISTANCE;

ANEMIA; CHRONIC DISEASE; COMORBIDITY; HEART FAILURE; HEMATINICS; HUMANS;

EID: 43749087331 PISSN: 13824147 EISSN: None Source Type: Journal
DOI: 10.1007/s10741-008-9093-y Document Type: Editorial

Times cited : (2)

References (6)

1
- 0034128813
- The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
- Silverberg DS, Wexler D, Blum M et al (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737-1744
- (2000) J Am Coll Cardiol , vol.35 , pp. 1737-1744
- Silverberg, D.S.¹ Wexler, D.² Blum, M.³

2
- 43749089210
- Anemia and chronic heart failure; implications and treatment options
- (in press)
- Anand IS (2008) Anemia and chronic heart failure; implications and treatment options. J Am Coll Cardiol 52 (in press)
- (2008) J Am Coll Cardiol , vol.52
- Anand, I.S.¹

3
- 28644437526
- Pathogenesis of anemia in cardiorenal disease
- Anand IS (2005) Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 6(Suppl 3):S13-S21
- (2005) Rev Cardiovasc Med , vol.6 , Issue.SUPPL. 3
- Anand, I.S.¹

4
- 33846669860
- Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis
- Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369:381-388
- (2007) Lancet , vol.369 , pp. 381-388
- Phrommintikul, A.¹ Haas, S.J.² Elsik, M.³ Krum, H.⁴

5
- 43749091154
- FDA A
- FDA A (2008) Additional trials showing increased mortality and/or tumor progression with EPOGEN®/PROCRIT® and Aranesp®. http://www.fda.gov/medwatch/safety/2008/epo_DHCP_03102008.pdf
- (2008) Additional Trials Showing Increased Mortality And/or Tumor Progression With EPOGEN®/PROCRIT® and Aranesp®

6
- 0027495285
- Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones
- Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC (1993) Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 70:357-362
- (1993) Br Heart J , vol.70 , pp. 357-362
- Anand, I.S.¹ Chandrashekhar, Y.² Ferrari, R.³ Poole-Wilson, P.A.⁴ Harris, P.C.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.